Astellas Pharma Gmbh

Banyu Pharmaceutical Co. Ltd

Msd K.k.

Keisuke Arakawa

Hiroyuki Takahashi

Teruyuki Nishimura

Takanori Koike

Susumu Yamaki

Itsuro Shimada

Kazushi Watanabe

Tomoaki Abe

Takahiro Nigawara

Tomoyoshi Imaizumi

Shigeki Kunikawa

Michinori Akaiwa

Takanobu Araki

Yoshiki Satake

Masashi Shimazaki

Makoto Ishikawa

Yasuhiro Sasaki

Kazuyuki Kuramoto

Yoshio Ogino

Morihiro Mitsuya

Tadashi Shimamura

Katsumasa Nonoshita

Makoto Bamba

Jun-ichi Eiki

Daisuke Tsukahara

Fumiko Sakai

Yoshikazu Nagae

Hiroshi Nakashima

Yuichi Sugimoto

Jun-Ichi Eiki

[Problem] Provided is a compound which is useful as an active ingredient of a pharmaceutical composition for treating lung cancer. [Means for Solution] The present inventors have studied a compound useful as an active ingredient of a pharmaceutical composition for treating lung cancer, and as a result, it was found that a quinazoline compound has an excellent G12C mutation KRAS inhibitory activity, and which can be used as a therapeutic agent for lung cancer, and thereby the present invention has been completed. The quinazoline compound of the present invention and a salt thereof may be used as the therapeutic agent for lung cancer.

Quinazoline compound

The present invention relates to a compound represented by formula (I): (wherein R, R, Rand Reach independently represent a hydrogen or halogen atom; Rand Reach independently represent a hydrogen atom or lower alkyl or together represent oxo; X represents C(O) or the like; Y represents an oxygen atom or the like; Z represents a hydrogen atom or the like; R represents 5- or 6-membered heteroaryl having 1-3 hetero atoms selected from the group consisting of nitrogen, sulfur and oxygen atoms, contained within a ring, or the like) or to a pharmaceutically acceptable salt thereof. 

Isoindolin-1-one derivative

A glucokinase activator is provided; and a remedy and/or a preventive for diabetes, or a remedy and/or a preventive for diabetes such as retinopathy, nephropathy, neurosis, ischemic cardiopathy, arteriosclerosis, and further a remedy and/or a preventive for obesity are provided. A glucokinase activator characterized by containing a 2-heteroaryl-substituted benzimidazole derivative of a general formula (I-0) or its pharmaceutically-acceptable salt: [in the formula, X represents a carbon atom or a nitrogen atom; (in the formula, X represents a carbon atom or a nitrogen atom); Rrepresents an aryl, etc.; Rrepresents a hydroxy, etc.; Rrepresents a &#x2014;Calkyl, etc.; Rrepresents a &#x2014;Calkyl, etc.; Xrepresents &#x2014;O&#x2014;, etc.; a indicates an integer of 1, 2 or 3; q indicates an integer of from 0 to 2; m indicates an integer of from 0 to 2].

2-heteroaryl-substituted benzimidazole derivative

The present invention provides a compound having a glucokinase activating action being useful for prevention or treatment of diabetes mellitus, etc. being represented by the formula (I): X is nitrogen atom, etc.; Y is oxygen atom, etc.; Ris an optionally substituted five to six-membered heteroaryl group, etc.; Ris hydrogen atom or fluorine atom; and ring A is a monocyclic or bicyclic heteroaryl group which may have a substituent represented by the formula (II)] or a pharmaceutically acceptable salt thereof.

Substituted quinazoline or pyridopyrimidine derivative

Growing community of inventors

Ibaraki, Japan

Keisuke Arakawa